A Bacterium That Lives Under Your Eyelid Could Be Engineered to Heal Corneal Injuries
Eye drops wash away. That is the fundamental problem with treating injuries and diseases on the eye's surface. Tears continually flush medications from the cornea, which is why conditions like corneal abrasions and dry eye disease often require multiple daily applications -- a regimen that is inconvenient, easy to forget, and limits how much drug actually reaches the tissue.
A team at the University of Pittsburgh School of Medicine has an alternative idea: instead of fighting the tears, use a microbe that already lives there.
The bacterium under your eyelid
Corynebacterium mastitidis is a harmless bacterium that naturally resides under the eyelid. It is part of the eye's normal microbiome -- the community of microorganisms that coexist with the body's own cells. The Pitt researchers, led by Anthony St. Leger, genetically modified this microbe to continuously secrete interleukin-10 (IL-10), a small protein that regulates inflammation.
The logic is elegant. Instead of applying a drug that gets washed away, apply a bacterium that stays put and continuously produces the therapeutic molecule. One application could, in theory, provide sustained drug delivery for as long as the engineered microbe persists.
Faster healing in mice
The proof-of-concept study, published in Cell Reports, tested the approach in mice with corneal scratches. Corneas treated with the engineered bacteria healed faster than those treated with unmodified bacteria or saline. When the researchers blocked the IL-10 receptor, the benefit disappeared -- confirming that the therapeutic effect depended specifically on IL-10, not on some other aspect of the bacteria's presence.
The team also created a version of the microbe that produces human IL-10 and tested it in lab-grown human corneal cells and human immune cells. The human IL-10-producing bacteria improved wound closure in the corneal cells and reduced inflammatory signaling in the immune cells. These are initial indications, not clinical proof, but they suggest the approach could potentially be adapted for human use.
A modular platform
One of the more interesting aspects of the system is its modularity. The genetic engineering framework was designed so that different therapeutic genes can be swapped in -- different cytokines, growth factors, or other proteins -- to tailor the therapy to specific eye conditions. A single bacterial chassis could potentially deliver treatments for dry eye, inflammatory disorders, or traumatic injuries, depending on which gene is inserted.
What still needs to happen
The technology is early-stage, and the gap between a mouse proof-of-concept and a human therapy is substantial. The researchers are direct about the hurdles that remain.
The most critical unresolved challenge is developing a reliable kill switch -- a way to safely and completely deactivate or remove the engineered bacteria when they are no longer needed. Introducing a living, genetically modified organism onto a patient's eye raises obvious safety questions. The bacteria would need to be controllable, not just effective.
Long-term persistence, potential interactions with the existing eye microbiome, and regulatory requirements for live biotherapeutics all represent significant development work ahead.
Still, the core concept -- using a native eye microbe as a persistent drug delivery vehicle -- addresses a real clinical problem. Conditions affecting the ocular surface, including severe dry eye and corneal injuries, affect millions of Americans annually, and current treatments are limited by the same tears-wash-everything-away problem that this approach aims to solve.